L-DOPA Induced Iron Accumulation in the Ventral Midbrain: The Roles of Sex and Iron Repletion
Objective: This study aims to investigate the impact of L-3,4-dihydroxyphenylalanine (L-DOPA) on ventral midbrain (VMB) iron levels under iron deficiency (ID) and repletion (IR) conditions…Safinamide as an Adjunct Therapy for Motor Symptoms and ON-Time Extension in Parkinson’s Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Objective: To evaluate the efficacy of safinamide as an adjunct therapy in improving motor symptoms and extending ON-time in patients with Parkinson’s disease (PD). Background:…Investigation of Baseline Factors Associated with a Favorable Response to Initial MAO-B Inhibitor Treatment in Parkinson’s Disease
Objective: This study aims to identify pre-treatment indicators for Parkinson’s disease (PD) patients who respond well to monoamine oxidase type B inhibitors (MAOBIs). Background: MAOBIs,…Treatment Stability Across Different ADD-ON Therapies in Fluctuating Parkinson’s Disease
Objective: This study investigates the efficacy and tolerability of selegiline (SL), rasagiline (RS), safinamide (SF), and opicapone (OP) in fluctuating PD patients, focusing on treatment…A multi-center, randomized, controlled study of the add-on effect of selegiline or zonisamide to L-dopa/DCI therapy in Parkinson’s disease (DATSZ-PD study)
Objective: To investigate the efficacy and safety for neuroprotection and disease modifying effect in selegiline(SL) or zonisamide(ZN) by using UPDRS, PDQ-39 and DAT -SPECT in…A matching-adjusted indirect comparison of efficacy and safety for safinamide versus rasagiline as adjunctive treatment to levodopa in Chinese patients with Parkinson’s disease
Objective: To compare efficacy and safety of safinamide and rasagiline as adjunctive treatment to levodopa in Chinese patients with Parkinson’s disease (PD) by matching-adjusted indirect…Selegiline drives autophagic secretion of α-synuclein
Objective: Our aim is to elucidate how selegiline drives extracellular secretion of α-synuclein (αS) and whether selegiline-induced αS secretion affects cell-to-cell transmission of αS. Background:…Dyskinesia and adherence to safinamide and opicapone in fluctuating patients with Parkinson’s disease: observational retrospective study
Objective: To assess differences in the new onset or worsening of baseline dyskinesia after the introduction of safinamide (SA) or opicapone (OP) as add-on therapy…Dopamine dysregulation syndrome in Parkinson’s disease controlled by safinamine
Objective: To describe a case of dopamine dysregulation syndrome managed by safinamide. Background: Dopamine dysregulation syndrome (DDS) is an uncommon non-motor symptom of Parkinson disease…SAFE-DBS – A monocentric, randomised, blind evaluation of safinamide in the perioperative period in Parkinsonian patients with deep brain stimulation
Objective: This monocentric, randomised, blind study is designed to evaluate the effect of safinamide on motor and neuropsychiatric symptoms in the 3 month perioperative period…
- 1
- 2
- 3
- …
- 7
- Next Page »